Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of a demarcation formula for Lybrido and Lybridos response in women with female sexual interest/arousal disorder
NL-OMON28721Phase 2Completed
- Sponsor
- Companion Diagnostics
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sildenafil + testosterone and Lybridos in female sexual arousal disorder (FSAD), sponsored by Companion Diagnostics. Primary endpoint: Change from placebo in frequency of satisfactory sexual events. Started Jan 2014; status: completed.
02
Drugs
sildenafil + testosteroneLybridos
03
Conditions
female sexual arousal disorder (FSAD)
Beyond the preview
Go deeper on NL-OMON28721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28721.